fibrotic interstitial lung disease

Evaluating Mycophenolate and Azathioprine in Fibrotic Interstitial Lung Disease: Insights from a Multicenter Retrospective Study

By MedXY 10/08/2026

This study reveals mycophenolate and azathioprine do not improve 3-year transplant-free survival or lung function in fibrotic ILD, with potential harm in select subtypes. Robust randomized trials remain essential for guiding immunosuppressive therapy.

news Respiratory

Acute Exacerbation in Fibrotic Interstitial Lung Disease: Key Recommendations from the 2026 International Working Group Report

By MedXY 08/02/2026

The 2026 international report redefines acute exacerbation across fibrotic interstitial lung diseases, proposes a framework to separate AE from other acute respiratory worsenings, and sets priorities for diagnosis, treatment, trial design, and research.

news Respiratory

Enhancing Treatment Evaluation in Fibrotic Interstitial Lung Disease: A Joint Model of Lung Function Decline and Mortality

By MedXY 07/09/2026

This article reviews a novel Bayesian joint mixed-effects model for analyzing lung function decline and mortality in fibrotic ILD, improving accuracy in estimating disease progression and treatment effects in clinical settings.

news Respiratory

International Validation of Electronic Nose Technology as a Diagnostic Tool for Fibrotic Interstitial Lung Diseases

By MedXY 06/02/2026

An international study found that electronic nose breath analysis can distinguish fibrotic interstitial lung disease subtypes with good accuracy, suggesting a promising noninvasive tool to support diagnosis.